ABSTRACT
Aim. To investigate the expressions of glutathione peroxidase 1 (GPX1) and caudal-related homeodomain transcription factor (CDX2) in GAC and their correlation with clinicopathological features and tumor cell proliferation. Methods. The expressions of GPX1, CDX2, and Ki67 were immunohistochemically evaluated in 172 GAC specimens. The association of GPX1 and CDX2 with patient's clinicopathological features and Ki67 positive rate was analyzed statistically. Results. In 172 cases of GAC, the expression of GPX1 was weaker than that in adjacent normal mucosa, and the expression of CDX2 was higher than that in adjacent normal mucosa. High expression GPX1 strong-expression was associated with differentiation, Lauren type, WHO type and extensive lymph node metastasis of GAC. High expression of CDX2 was associated with differentiation, Lauren type, WHO type, extensive lymph node metastasis, and TNM of GAC. Survival curves showed that expressions of GPX1 and CDX2 were factors of good outcome (P = .03 and .02, resp.). According to multivariate analysis, only lymph node metastasis, TNM stage, and CDX2 expression were independently associated with survival. In addition, a strong association of GPX1 expression was noted with Ki67 and CDX2. Conclusions. The expression of GPX1 and CDX2 may play a role in the carcinogenesis, differentiation, and progression of GAC, and CDX2 may be an independent prognostic factor.
ABSTRACT
OBJECTIVE: To explore whether cancer cells abide by the mechanism of epithelial-mesenchymal transition (EMT) in the process of invasion and metastasis by comparing histology and protein expression of E-cadherin and vimentin among primary, metastatic carcinomas and their emboli. METHODS: A total of 68 tissue specimens in 59 cases of primary adenocarcinoma or squamous cell carcinoma and their lymphatic metastasis were collected, of which there were 13 well differentiated, 11 moderately differentiated, 30 poorly differentiated tumors and 14 lymphatic metastases. The morphology and the expression of E-cadherin and vimentin proteins were assessed by H-E stain and immunohistochemistry. RESULTS: The overall morphology of the primary cancers and their tumor emboli was similar. Among 54 primary cancers, 50 cases were positive for E-cadherin and 22 cases were positive for vimentin. Fifty-one cases were positive for E-cadherin and 22 cases were positive for vimentin in the tumor emboli, with no statistical difference (P = 0.804, P = 0.842). Among 14 cases of lymphatic metastasis, 12 cases were positive for E-cadherin and 6 cases were positive for vimentin, and the tumor emboli in 12 cases were positive for E-cadherin and 7 cases were positive for vimentin, with statistical difference (P = 0.084, P = 0.878). There were no significant difference of E-cadherin and vimentin protein expression between the cancer tissue and its emboli (P = 0.410, P = 0.824). A subset of tumor cells in cancer emboli expressed E-cadherin at a high level without vimentin expression, whereas other cells in tumor emboli showed an opposite expression pattern. CONCLUSIONS: There is no significant difference of EMT characteristics among primary cancer, lymphatic metastases and their cancer emboli. Cancer thrombus contains both EMT and non-EMT cells. Further studies are required to elucidate the role of EMT in the processes of tumor invasion and metastasis.
